Alessandro Gronchi: A new study is on the horizon for sarcomas
Alessandro Gronchi, Chair of the Department of Surgical Oncology at the National Cancer Institute of Milan, shared a post on LinkedIn:
“At ESMO – European Society for Medical Oncology Sarcoma and Rare Cancers Meeting in Lugano a full house attended the engaging session about neoadjuvant therapies in high-risk soft tissue sarcoma.
A new study is on the horizon which will test the combination of immune checkpoint inhibitors and anthracycline-based chemotherapy +/- radiotherapy.
All attendees agreed that this is the study to do in sarcomas. And a parallel observational study will also be done to include all patients treated off randomized trial at the participating institutions, taking the example of STREXIT and STREXIT2 in retroperitoneal sarcoma.
This incredible sarcoma community can make it!”
Alessandro Gronchi
More posts featuring Alessandro Gronchi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023